-
1
-
2دورية أكاديمية
المؤلفون: Sinakos E., Kountouras D., Koskinas J., Zachou K., Karatapanis S., Triantos C., Vassiliadis T., Goulis I., Kourakli A., Vlachaki E., Toli B., Tampaki M., Arvaniti P., Tsiaoussis G., Bellou A., Kattamis A., Maragkos K., Petropoulou F., Dalekos G.N., Akriviadis E., Papatheodoridis G.V.
المصدر: British Journal of Haematology ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018745432&doi=10.1111%2fbjh.14640&partnerID=40&md5=6314541aca3316573098063af32c40edTest
مصطلحات موضوعية: daclatasvir, dasabuvir, deferiprone, deferoxamine, ledipasvir plus sofosbuvir, ombitasvir plus paritaprevir plus ritonavir, ribavirin, simeprevir, sofosbuvir, antivirus agent, BMS-790052, imidazole derivative, adult, antiviral therapy, Article, blood transfusion, chelation therapy, chronic hepatitis C, clinical article, combination drug therapy, drug efficacy, drug safety, drug tolerability, female, Hepatitis C virus genotype 1, Hepatitis C virus genotype 2, Hepatitis C virus genotype 3, Hepatitis C virus genotype 4, human, liver cirrhosis
-
3
-
4